ProfileGDS5678 / 1453028_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 80% 81% 83% 78% 82% 82% 81% 80% 80% 81% 83% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9033982
GSM967853U87-EV human glioblastoma xenograft - Control 25.7528680
GSM967854U87-EV human glioblastoma xenograft - Control 35.7887881
GSM967855U87-EV human glioblastoma xenograft - Control 46.2003983
GSM967856U87-EV human glioblastoma xenograft - Control 55.3584578
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7342682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8250782
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7786381
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6085580
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7644280
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7820681
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1122283
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.535879
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4497979